Journal:Acta Cryst D:S2059798322007082
From Proteopedia
(Difference between revisions)

| Line 12: | Line 12: | ||
<scene name='91/917471/Cv2/8'>The MPO catalytic site</scene> carries an iron-containing heme group. The heme group of MPO and the near binding of the thiocyanate, a natural substrate, and paroxetine, an inhibitor, as found in the monomer with chain A are shown. Amino acid numbering is based on the pro-MPO crystal structure numbering, including signal and pro-peptide. Our structure also contains <scene name='91/917471/Cv2/9'>bound paroxetine</scene>, a recently discovered inhibitor of MPO, previously used as anti-depressant. The bound paroxetine was always found in the presence of <scene name='91/917471/Cv2/10'>thiocyanate</scene>, a physiological substrate of MPO. A lot of effort has been undertaken into inhibitor design, as things can also go wrong with MPO. When things go wrong, MPO is released into the extracellular fluid. This circulating MPO damages host tissue as the reaction products of MPO can oxidize biomolecules (lipids, DNA and proteins). So, MPO is involved in a lot of pathologies, either as a source or to make the symptoms worse of existing pathologies, creating a large interest into the design of molecules in order to block this circulating MPO. | <scene name='91/917471/Cv2/8'>The MPO catalytic site</scene> carries an iron-containing heme group. The heme group of MPO and the near binding of the thiocyanate, a natural substrate, and paroxetine, an inhibitor, as found in the monomer with chain A are shown. Amino acid numbering is based on the pro-MPO crystal structure numbering, including signal and pro-peptide. Our structure also contains <scene name='91/917471/Cv2/9'>bound paroxetine</scene>, a recently discovered inhibitor of MPO, previously used as anti-depressant. The bound paroxetine was always found in the presence of <scene name='91/917471/Cv2/10'>thiocyanate</scene>, a physiological substrate of MPO. A lot of effort has been undertaken into inhibitor design, as things can also go wrong with MPO. When things go wrong, MPO is released into the extracellular fluid. This circulating MPO damages host tissue as the reaction products of MPO can oxidize biomolecules (lipids, DNA and proteins). So, MPO is involved in a lot of pathologies, either as a source or to make the symptoms worse of existing pathologies, creating a large interest into the design of molecules in order to block this circulating MPO. | ||
| - | <scene name='91/917471/Cv2/13'>Superposition</scene> of PDB entry [[1dnu]] (blue) containing thiocyanate (SCN-) with chain A of the MPO crystal structure (wheat), bound to SCN- and paroxetine. | + | <scene name='91/917471/Cv2/13'>Superposition</scene> of PDB entry [[1dnu]] (blue) containing thiocyanate (SCN-) with chain A of the MPO crystal structure (wheat), bound to SCN- and paroxetine. |
| + | <jmol><jmolButton><script>display:A</script><text>only present MPO structure</text></jmolButton><jmolButton><script>display:B</script><text>only 1dnu</text></jmolButton><jmolButton><script>display all</script><text>both present MPO structure and 1dnu</text></jmolButton></jmol> | ||
<b>References</b><br> | <b>References</b><br> | ||
Revision as of 14:20, 26 July 2022
| |||||||||||
This page complements a publication in scientific journals and is one of the Proteopedia's Interactive 3D Complement pages. For aditional details please see I3DC.
